ReviewDrugs2023

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.

Javier P Gisbert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.